OTLK and OTLKW Related Headlines
Go Back- Outlook Therapeutics (OTLK) Receives EU Positive CHMP Opinion for ONS-5010
- Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
- Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
- Outlook Therapeutics (OTLK) Announces Effective Date for 1-for-20 Reverse Stock Split
- Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
- Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
- Outlook Therapeutics (OTLK) Submits Special Protocol Assessment to FDA for Non-Inferiority Study of ONS-5010
- Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010
- Outlook Therapeutics (OTLK) Announces Strategic Organizational Realignment
- Outlook Therapeutics® Announces Strategic Organizational Realignment
- Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference
- Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
- Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
- Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
- Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
OTLK and OTLKW Related Press Releases
Go Back- Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
- Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
- Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
- Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
- Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010
- Outlook Therapeutics® Announces Strategic Organizational Realignment
- Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference
- Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
- Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
- Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
- Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
